China's pharmaceutical industry surges on ageing demand and global expansion, with revenue forecast to top US$2.1 trillion by ...

Bayer AG’s pharmaceuticals unit is on track for a return to growth as new drugs for cancer and kidney disease offset sales ...

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

At the JPMorgan Healthcare Conference, Genmab emphasized a long-term growth strategy centered on disciplined R&D investment ...

ANI Pharmaceuticals (NASDAQ:ANIP) outlined plans to accelerate its shift toward rare disease medicines while maintaining ...

For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

The pharmaceuticals and agriculture group Bayer aims to return its pharmaceuticals business to mid-single-digit percentage ...

A worldwide leader in injectable drug administration will be the newest company to set up shop in Greenfield, and anticipates ...

E-commerce pet care giant Chewy Inc. (NYSE:CHWY) could show continued diversification into high-gross margin segments when it reports first-quarter financial results Wednesday before the market opens.

We came across a bullish thesis on Catalyst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will ...